Clinical Trials on 24-hour Dietary Recall in New Zealand

Total 6 results

Australian and New Zealand Intensive Care Research...
Intensive Care Foundation, Australia

Completed

TEAM: Trial of Early Activity and Mobilization (TEAM)

Critically Ill Adults Ventilated >24 Hours in Intensive Care

Australia, New Zealand
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
Vanda Pharmaceuticals

Completed

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Blindness | Non-24 Hour Sleep-Wake Disorder

United States
Wan-Chuan Tsai

Completed

Low-Phosphate Diet and Fibroblast Growth Factor-23 Level

Hyperphosphatemia | Dietary Intervention | Chronic Kidney Disease Requiring Chronic Dialysis | Elevated Fibroblast Growth Factor-23

Taiwan

3

Subscribe